Until recently, major advances in drug development have been hampered by a lack of proper cell and tissue models; but the introduction of organoid technology has revolutionized this field. At the level of the gastrointestinal tract, the so-called mini-gut comprises all major cell types of native intestine and recapitulates the composition and function of native intestinal epithelium. The mini-gut can be classified as an intestinal organoid (IO), derived from pluripotent stem cells, or as an enteroid, consisting only of epithelial cells and generated from adult stem cells. Both classifications have been used as models to develop drugs against cystic fibrosis, cancer and infectious disease, as well as for drug screening, personalized medicine and the development of new medical tools. In this review, we highlight and discuss the importance of mini-guts for drug development and point out their limitations and future prospects.The importance of mini-guts for drug development to combat cystic fibrosis, cancer and infectious disease, in addition to their use in drug screening, personalized medicine and developing new medical tools for drug development are highlighted.

Additional Metadata
Persistent URL dx.doi.org/10.1016/j.drudis.2019.06.006, hdl.handle.net/1765/117516
Journal Drug Discovery Today
Citation
Yin, Y, de Jonge, H.R, Wu, X. (Xin), & Yin, Y.-L. (Yu-Long). (2019). Mini-gut: a promising model for drug development. Drug Discovery Today (Vol. In Press, Corrected Proof). doi:10.1016/j.drudis.2019.06.006